

PERSONAL INFORMATION

Dr Anna CHIOTI - MD, MPH, MBA

WORK EXPERIENCE

Aug 2019 – Present

Head of Division Pharmacy and MedicinesLuxembourg Health Directorate - Direction de la santé (<https://sante.public.lu/>)

- Leading the scientific, technical and regulatory activities aiming to advise the Ministry of Health to fulfil its NCA obligations for human and veterinary medicines as well as other health products, including medical devices, IVD, cosmetics and medicinal cannabis.

Business or sector Government administration / Healthcare

Mar 2018 – Present

MD in charge of the development of the Luxembourg Agency for Medicines and Health ProductsLuxembourg Health Directorate - Direction de la santé (<https://sante.public.lu/>)

- Piloting the set-up of a new public administration that will act as the NCA for medicines and health products in Luxembourg.

Business or sector Government administration / Healthcare

Mar 2022 – Present

Science & Innovation Panel Member & ChairpersonInnovative Health Initiative (IHI) (www.ih.europa.eu/)

- The Science and Innovation Panel (SIP) provides the Governing Board with advice on matters relevant to IHI's research and innovation activities.

Business or sector Public-private partnership (PPP) / Research

Jan 2022 – Present

Founding Board Member

EUPATI

- EUPATI Luxembourg is a platform that brings together patients, the academic world, the pharmaceutical industry and all other persons interested in the objectives of EUPATI.
- This platform aims to enable patients to better understand the world of biomedical research, the world of drug research and development and the functioning of the Luxembourg health system. The objective of EUPATI Luxembourg is to raise awareness and train patients so that they become active players in biomedical research and in the Luxembourg health system.
- Another role of EUPATI Luxembourg is to facilitate communication between patients, researchers, healthcare professionals and the Luxembourg health-related authorities.

Business or sector NGO / non-profit

Oct 2016 – Dec 2021

Scientific Committee MemberInnovative Medicines Initiative (IMI) (www.imi.europa.eu)

- The Scientific Committee gives strategic science-based recommendations to IMI and advises on the continued relevance of the Strategic Research Agenda and the scientific priorities, which are the basis for the Call Topics.

Business or sector Public-private partnership (PPP) / Research

Nov 2017 – Present

President, Founding Board Member

Luxembourg Public Health Association (LUXPHA)

- Guiding the set-up of the scientific association, which aims at bringing together researchers, health professionals and officials in the field of public health.

Business or sector Non-profit organization / Public Health / Research

- Dec 2014 – Present **Associate Editor**
EPMA Journal (<https://www.springer.com/journal/13167>)
- Feb 2019 – Aug 2019 **Associate Head of Division of Pharmacy and Medicines**
Luxembourg Health Directorate - Direction de la santé (<https://sante.public.lu/>)
Business or sector Government administration / Healthcare
- Jan 2012 – Oct 2018 **Board Member**
EFGCP – European Forum for Good Clinical Practice (<https://efgcp.eu/>)
▪ EFGCP enables partnership between patients, researchers and other healthcare stakeholders to ensure ethical awareness as well as research integrity in health research and facilitates transparent implementation of preventive health measures & treatments.
Business or sector Not-for-profit organisation / Health / Research Ethics
- Aug 2017 – Feb 2018 **Associate Director, Department of Population Health**
Luxembourg Institute of Health (<https://www.lih.lu/>)
Business or sector Public Research Institute
- Nov 2016 – Feb 2018 **Executive Board Member**
EuroHealthNet (<https://eurohealthnet.eu/>)
▪ Addressing the social determinants of health to help build fairer, healthier, and more sustainable communities for all.
Business or sector Not-for-profit organisation / Public Health
- Dec 2016 – Jan 2018 **Board Member**
Luxembourg Agency for Research Integrity (LARI) (<https://lari.lu/>)
▪ Contributed to set up the national agency promoting and investigating research integrity in Luxembourg.
Business or sector Not-for-profit organisation / Research
- Jan 2016 – Jan 2018 **Editorial board member**
International Journal of Clinical Research & Trials
- Sep 2016 – Aug 2017 **Director of Population Health Department (ad int.)**
Luxembourg Institute of Health (<https://www.lih.lu/>)
Business or sector Public Research Institute
- Mar 2015 – Sep 2016 **Director of Operations, Department of Population Health**
Luxembourg Institute of Health (<https://www.lih.lu/>)
Business or sector Public Research Institute
- Sep 2010 – Sep 2016 **Member of Scientific Council**
Centre François Baclesse – CHEM (<https://www.baclesse.lu/>)
▪ Providing scientific guidance on questions relating to the medical orientation of the Center, the engagement of doctors, relations between doctors, medical ethics and the monitoring and evaluation of medical practices, care and other forms of care.
Business or sector Hospital / Radiotherapy
- Apr 2010 – Sep 2016 **Head of the Clinical Investigation and Epidemiological Center (CIEC)**
Luxembourg Institute of Health (<https://www.lih.lu/>)

- Assist and support clinical research projects by setting up a network of partnerships and bringing together key players in the scientific community: medical doctors, researchers, healthcare professionals, hospitals, pharmaceutical industry and universities.
- Ensure the clinical expertise for the development of innovative therapeutic and diagnostic procedures at a national level, in the Greater Region and at a European and international level.

Business or sector Public Research Institute

Dec 2014 – Mar 2016

Co-Chair Medical technology Working Party

EFGCP – European Forum for Good Clinical Practice (<https://efgcp.eu/>)

Business or sector Not-for-profit organisation / Health / Research Ethics

May 2012 – Dec 2015

Chair of Network Committee

ECRIN (European Clinical Research Infrastructure Network)

- Contributed to build a consistent organisation for clinical research in Europe, providing generic tools and services to multinational studies, and supporting the construction of pan-European disease-oriented networks (e.g. WP2 expansion, capacity building and funding).

Business or sector Not-for-profit organisation / Clinical trials

Feb 2013 – Oct 2014

Advisory Board Member

European Society for Translational Medicine (EUSTM) (<https://eutranslationalmedicine.org/>)

Business or sector Not-for-profit organisation / R&D

Sep 2008 – Apr 2010

Therapeutic Area Leader Oncology & Hospital Care

AstraZeneca (<https://www.astrazeneca.com/>)

- Manages the Therapeutic Area Unit in order to perform the studies in a reliable, productive and cost effective way. Selects, proposes, and develops relevant international & local clinical studies, based on scientific, strategic and commercial criteria.
- Builds and maintains visibility and excellent long-term professional relationships with universities, opinion leaders and key investigators. Provides high-quality medical advice and assistance to other departments (Marketing, Sales, and Public Affairs).

Business or sector Pharmaceutical industry

Dec 2006 – Sep 2008

Therapeutic Area Leader Oncology

AstraZeneca (<https://www.astrazeneca.com/>)

- Manages the Therapeutic Area Unit in order to perform the studies in a reliable, productive and cost effective way. Selects, proposes, and develops relevant international & local clinical studies, based on scientific, strategic and commercial criteria.
- Builds and maintains visibility and excellent long-term professional relationships with universities, opinion leaders and key investigators. Provides high-quality medical advice and assistance to other departments (Marketing, Sales, and Public Affairs).

Business or sector Pharmaceutical industry

Jul 2003 – Nov 2006

Medical Manager Cardio-Metabolic Diseases

Merck Sharp & Dohme (MSD) (<https://www.msd.com/>)

- Actively create and maintain relationships with major national and international opinion leaders.
- Contribute to achieve the approved profit plan for the cardiovascular portfolio products through scientific support in the development of Marketing Strategy and Marketing Plan.
- Contribute to product and disease-related knowledge of Sales Forces. Ensure medical support on the cardiovascular portfolio products to internal and external customers.

Business or sector Pharmaceutical industry

Jan 2003 – Jul 2003

Product Medical Manager CV & NSAIDs

Innovex (former Quintiles Innovex and currently IQVIA: <https://www.iqvia.com/>)

- Develop and execute marketing programs for CV & NSAIDs products portfolio.
- Ensure disease-related and product knowledge for Sales Forces
- Coordinate activities in production, sales, advertising, promotion, marketing research, purchasing, distribution, package development, and finance.

Business or sector Pharmaceutical industry

Oct 1999 – Jan 2003

General Practitioner, MD

Self-employed / Private clinic / Hospital

Business or sector Healthcare professional

EDUCATION AND TRAINING

Q2 2022

Big Data for Social Good

Harvard Business School Online

Q2 2021

Driving Health Care Strategy: Business Insights from Inside the Ecosystem

Harvard Medical School

Oct 2020

Inquiry-Driven Leadership

MIT Sloan School of Management

Q3 – Q4

HMX Fundamentals/Pro online certificate program: Immunology - Immuno-oncology, Medicine

Harvard Medical School

Q3 – Q4 2020

HMX Fundamentals/Pro online certificate program: Genetics - Cancer Genomics, Medicine

Harvard Medical School

Q3 – Q4 2020

HMX Fundamentals/Pro online certificate program: Genetics - Essentials, Medicine

Harvard Medical School

Q3 – Q4 2020

HMX Fundamentals/Pro online certificate program: Pharmacology - Essentials, Medicine

Harvard Medical School

Sept 2018 – Sept 2020

Master of Business Administration - MBA

Luxembourg School of Business

- Leadership and general management

Q1 – Q2 2019

Artificial Intelligence: Implications for Business Strategy

MIT Sloan Executive Education

2000 - 2002

Public Health Specialisation Diploma (MSc)

Université Catholique de Louvain, Belgium

1990 - 1999

MD + Specialisation GP, Faculty of Medicine

Université Catholique de Louvain, Belgium

ADDITIONAL INFORMATION
Publications

- Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination Survey in Luxembourg. H Samouda, M Ruiz-Castell, M Karimi, V Bocquet, A Kuemmerle, **A Chioti**, F Dadoun, S Stranges. *Diabetes Metab*. 2019 Apr;45(2):140-151.
- Challenges and benefits of integrating diverse sampling strategies in the observation of cardiovascular risk factors (ORISCAV-LUX 2) study. A Alkerwi, J Pastore, N Sauvageot, G Le Coroller, V Bocquet, M d'Incau, G Aguayo, B Appenzeller, D Bejko, T Bohn, L Malisoux, S Couffignal, S Noppe, C Delagardelle, J Beissel, **A Chioti**, S Stranges, J-C Schmit. *BMC Med Res Methodol*. 2019 Feb 4; 19(1):27.
- Comparative analysis of the association between 35 frailty scores and cardiovascular events, cancer, and total mortality in an elderly general population in England: An observational study. GA Aguayo, MT Vaillant, A-F Donneau, A Schritz, S Stranges, L Malisoux, **A Chioti**, M Guillaume, M Muller, D R Witte. *PLoS Med* 2018 Mar 27;15(3): e1002543.
- Geographical variation of overweight, obesity and related risk factors: Findings from the European Health Examination Survey in Luxembourg, 2013-2015. Samouda H, Ruiz-Castell M, Bocquet V, Kuemmerle A, **Chioti A**, Dadoun F, Kandala NB, Stranges S. *PLoS One*. 2018 Jun 14;13(6) : e0197021.
- Comparative analysis of the association between 35 frailty scores and cardiovascular events, cancer, and total mortality in an elderly general population in England: An observational study. Aguayo GA, Vaillant MT, Donneau AF, Schritz A, Stranges S, Malisoux L, **Chioti A**, Guillaume M, Muller M, Witte DR. *PLoS Med*. 2018 Mar 27;15(3):e1002543.
- Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination Survey in Luxembourg. Samouda H, Ruiz-Castell M, Karimi M, Bocquet V, Kuemmerle A, **Chioti A**, Dadoun F, Stranges S. *Diabetes Metab*. 2017 Dec 1. pii: S1262-3636(17)30581-5.
- 1986-2016: 30 years of pregnancy outcomes surveillance in HIV-Positive women in Luxembourg. A Fischer, V Etienne, JC Schmit, V Arendt, T Staub, R Hemmer, C Michaux, M Gantenbein, **A Chioti**. *European Journal of Public Health*, Volume 26, Issue suppl_1, 1 November 2016.
- Advice on lifestyle changes (diet, red wine and physical activity) does not affect internal carotid and middle cerebral artery blood flow velocity in patients with carotid arteriosclerosis in a randomised controlled trial. Droste DW, Iliescu C, Vaillant M, Gantenbein M, De Bremaeker N, Lieunard C, Velez T, Meyer M, Guth T, Kuemmerle A, **Chioti A**. *Cerebrovasc Dis* 2014; 37:368–375.
- A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial. Droste DW, Iliescu C, Vaillant M, Gantenbein M, De BN, Lieunard C, Velez T, Meyer M, Guth T, Kuemmerle A, Gilson G, **Chioti A**. *Nutr J* 2013; 12:147-155.
- A Daily Glass of Red Wine and Lifestyle Changes Do Not Affect Arterial Blood Pressure and Heart Rate in Patients with Carotid Arteriosclerosis after 4 and 20 Weeks. Droste DW, Iliescu C, Vaillant M, Gantenbein M, De Bremaeker N, Lieunard C, Velez T, Meyer M, Guth T, Kuemmerle A, **Chioti A**. *Cerebrovascular Diseases Extra* 2013; 3:121-129.
- Lifestyle counseling in patients with carotid arteriosclerosis from Luxemburg should focus more on the reduction of sugar, sodium and saturated fat consumption Droste DW, Iliescu C, Vaillant M, Gantenbein M, De Bremaeker N, Lieunard C, Velez T, Meyer M, Guth T, Kuemmerle A, **Chioti A**. *Bull Soc Sci Med Grand Duché Luxemb*. 2013; (1):2838.
- Prevalence and treatment of anaemia in cancer patients in Luxembourg. Gantenbein M, Untereiner M, **Chioti A**, Rauh S, Berchem G, Jacob F, Plawny L, Dewilde S, Burie D, Frederick B. Poster Presentation at the 26th General Meeting of the Belgian Hematological Society, Liège, January 28-29, 2011.
- The Cariatide study: evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor medication in postmenopausal breast cancer patients: baseline data. Neven P., Tanner M., Kreienberg R., Atkins L., Marty M., **Chioti A**, Markopoulos C. *EJC Supplements* 2010; 8 (3): 78.

Honours and
awards

- Excellence Award - Luxembourg School of Business, Sep 2020. For outstanding performance and exceptional commitment to team work on MBA Consulting Project.
- Excellence Award - Fanuc Europe Corporation, S.A. Sep 2020. Business Consulting Project MBA winning team
- Award of Economic Diplomacy, Cercle International Diplomatique et Consulaire (CIDIC), in the frame of Luxembourg EU Presidency, Belgium & Luxembourg 2015.
 - Award for Advancing Public Awareness in Clinical Research, Association of Clinical Research Professionals (ACRP), San Antonio, Texas, USA, 2014.
 - Award for Outstanding Contribution to Luxembourg Healthcare and Life Sciences Community, Luxembourg 2014.
 - Clinical Trials Honour Roll 2012 – AccessCR, May 2012
 - Clinical Trials Honour Roll 2011 – AccessCR, May 2011